Panacea Acquisition Corp. II (PANA) Prices $150M IPO

Panacea Acquisition Corp. II announced the pricing of its $150 million IPO and its shares are expected to begin trading on the Nasdaq under the symbol “PANA”, Wednesday, April 7.

The new company aims to combine with an innovative biotechnology business that is domiciled in North America or Europe. Panacea II is led by CEO and Chairman Oleg Nodelman, CFO Scott Perlen, COO Scott Platshon, CIO Caroline Stout, and Secretary Sarah Marriott.

Total SPAC deal count for 2021 year-to-date is now 301. This offering is expected to close on Friday April 9.

Cowen is serving as the sole book-running manager for the offering. Skadden, Arps, Slate, Meagher & Flom LLP is serving as Issuer’s Counsel with Greenberg Traurig LLP serving as Underwriter’s Counsel. WithumSmith+Brown, PC serves as auditor. Continental Stock Transfer & Trust Company is acting as trustee.